Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Rocklatan (netarsudil 0.02% and latanoprost 0.005%) — DRUG
Additional intraocular eye pressure lowering post-Hydrus
Systane — DRUG
Placebo Comparator (artificial tears)

The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.

Placebo Comparator: Placebo Comparator Systane Artificial Tears
Comparator arm is Systane artificial tears
Active Comparator: FDA Approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%)
FDA approved Rocklatan (netarsudil 0.02% and latanoprost 0.005%) is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Mean diurnal intraocular pressure change from baseline [ Time Frame: After 28 days up to 35 days post initiation of Rocklatan vs placebo comparator ]

Facility	City	State	ZIP	Site coordinators
Center for Sight	Las Vegas	Nevada	89145	Clinical Research Manager [email protected] 702-724-2005 Clinical Research Coordinator

By research site